title: Effects of one year treatment of sibutramine on insulin resistance parameters in type 2 diabetic patients.
abstract: OBJECTIVE
  Comparison of the effects of one year treatment with sibutramine compared to placebo on insulin resistance parameters, body weight, glycemic control, and lipid profile, in type 2 diabetic patients.
  
  
  METHODS
  Two hundred and forty-six patients with uncontrolled type 2 diabetes mellitus in therapy with different oral hypoglycemic agents or insulin were enrolled in this study and randomised to take sibutramine 10 mg or placebo for one year. We evaluated at baseline, and after 3, 6, 9, and 12 months these parameters: homeostasis model assessment insulin resistance index (HOMA-IR), retinol binding protein-4 (RBP-4), resistin, visfatin, and high sensitivity-C reactive protein (Hs-CRP), body weight, body mass index (BMI), glycated hemoglobin (HbA(₁c)), fasting plasma glucose (FPG), post-prandial plasma glucose (PPG), fasting plasma insulin (FPI), total cholesterol (TC), low density lipoprotein-cholesterol (LDL-C), high density lipoprotein-cholesterol (HDL-C), and triglycerides (T(g)).
  
  
  RESULTS
  A faster decrease of HOMA-IR, resistin, and RBP-4 was recorded with sibutramine compared to the control group. We observed a significant decrease of Hs-CRP in both groups, and a faster improvement of HbA(₁c), FPG and PPG with sibutramine compared to the control group; furthermore we recorded a decrease of FPI, TC, LDL-C, body weight, and BMI in the sibutramine group, but not in the control group.
  
  
  CONCLUSIONS
  Sibutramine gave a faster improvement of insulin resistance parameters and glycemic control compared to placebo; furthermore sibutramine gave also an improvement of lipid profile, and body weight.
authors.affiliation: Department of Internal Medicine and Therapeutics, University of Pavia, Pavia, P.le C. Golgi, 2-27100 Pavia, Italy. giuseppe.derosa@unipv.it
authors.forename: Giuseppe
authors.initials: G
authors.lastname: Derosa
authors.forename: Pamela
authors.initials: P
authors.lastname: Maffioli
authors.forename: Ilaria
authors.initials: I
authors.lastname: Ferrari
authors.forename: Ilaria
authors.initials: I
authors.lastname: Palumbo
authors.forename: Sabrina
authors.initials: S
authors.lastname: Randazzo
authors.forename: Angela
authors.initials: A
authors.lastname: D'Angelo
authors.forename: Arrigo F G
authors.initials: AF
authors.lastname: Cicero
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D001067:Appetite Depressants / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*; D001786:Blood Glucose / Q000032:analysis; D015992:Body Mass Index; D001835:Body Weight / Q000187:drug effects; D003503:Cyclobutanes / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*; D003924:Diabetes Mellitus, Type 2 / Q000150:complications* / Q000188:drug therapy / Q000378:metabolism; D005260:Female; D006442:Glycated Hemoglobin / Q000032:analysis*; D006801:Humans; D007004:Hypoglycemic Agents / Q000627:therapeutic use; D007328:Insulin / Q000097:blood / Q000627:therapeutic use; D007333:Insulin Resistance; D008055:Lipids / Q000097:blood; D008297:Male; D008875:Middle Aged; D009765:Obesity / Q000150:complications / Q000188:drug therapy* / Q000378:metabolism; D052243:Resistin / Q000097:blood; D055815:Young Adult
chemical_list: D001067:Appetite Depressants; D001786:Blood Glucose; D003503:Cyclobutanes; D006442:Glycated Hemoglobin; D007004:Hypoglycemic Agents; D007328:Insulin; D008055:Lipids; D052243:Resistin; C058254:sibutramine